At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Mar 10, 2026 at 22:54 ET
Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants for 402,468 additional shares at $80.999, raising approximately $625 million in gross proceeds. The funds will support clinical development, commercial readiness, and general corporate purposes, with a 30-day underwriter option to purchase up to an additional 1,157,407 shares.
- Priced public offering of 7,313,582 common shares at $81.00 per share
- Pre-funded warrants issued for 402,468 shares at $80.999, exercisable immediately at $0.001 per share
- Total gross proceeds: ~$625 million (before expenses)
- Underwriters granted 30-day option to purchase up to 1,157,407 additional shares
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access